KRYS
Krystal Biotech, Inc.Company Information
- Company Name
- Krystal Biotech, Inc.
- CIK
- CIK0001711279
- Category
- Large accelerated filer
- Ticker: Exchange
- KRYS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- KRYS
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-04
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 271,345
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 28,772,294
- Shares outstanding
- 29,529,000
- Ownership
- 97.44%
Earnings Market Reaction
- Filing date
- 2026-08-03
- Price on filing date
- —
- 1-month reaction
- 12.44%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 428 | 501 | 496 | 393 | 354 | 309 | 345 | 374 | 346 | 359 | 358 | 373 | ||||||
| Available For Sale Securities Debt Securities Current | 418 | 322 | 331 | 338 | 328 | 308 | 253 | 214 | 214 | 179 | 174 | 189 | ||||||
| Accounts Receivable Net Current | 139 | 127 | 127 | 130 | 111 | 103 | 105 | 97 | 103 | 105 | 42 | 9 | ||||||
| Inventory Net | 46 | 43 | 40 | 38 | 31 | 30 | 27 | 19 | 12 | 11 | 7 | 5 | ||||||
| Prepaid Taxes | 15 | 11 | 14 | 10 | - | - | 2 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 14 | 16 | 15 | 17 | 17 | 17 | 12 | 9 | 8 | 6 | 7 | 5 | ||||||
| Assets Current | 1,060 | 1,020 | 1,025 | 926 | 841 | 767 | 742 | 713 | 683 | 602 | 588 | 582 | ||||||
| Property Plant And Equipment Net | 154 | 154 | 151 | 149 | 150 | 151 | 155 | 157 | 159 | 160 | 161 | 164 | ||||||
| Long Term Investments | 257 | 193 | 128 | 133 | 139 | 148 | 152 | 106 | 69 | 84 | 62 | 37 | ||||||
| Operating Lease Right Of Use Asset | 7 | 7 | 7 | 7 | 8 | 8 | 6 | 6 | 7 | 7 | 7 | 7 | ||||||
| Deferred Income Tax Assets Net | 23 | 23 | 23 | 25 | - | - | 0 | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 1,501 | 1,397 | 1,334 | 1,240 | 1,138 | 1,074 | 1,056 | 982 | 918 | 853 | 818 | 790 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 7 | 4 | 3 | 2 | 7 | 3 | 5 | 6 | 5 | 5 | 4 | 4 | ||||||
| Operating Lease Liability Current | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 36 | 31 | 40 | 32 | 27 | 28 | 59 | 53 | 43 | 30 | 22 | 22 | ||||||
| Liabilities Current | 127 | 108 | 103 | 91 | 87 | 79 | 102 | 90 | 72 | 48 | 33 | 28 | ||||||
| Operating Lease Liability Noncurrent | 7 | 7 | 8 | 8 | 8 | 8 | 6 | 6 | 6 | 6 | 7 | 7 | ||||||
| Other Liabilities Noncurrent | 7 | 5 | 4 | 3 | 3 | 2 | 1 | 1 | 1 | - | 0 | - | ||||||
| Liabilities | 142 | 120 | 114 | 102 | 98 | 90 | 109 | 96 | 79 | 54 | 40 | 34 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,229 | 1,198 | 1,194 | 1,164 | 1,146 | 1,129 | 1,127 | 1,110 | 1,093 | 1,068 | 1,048 | 1,035 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -4 | -2 | 1 | 1 | 1 | 0 | -0 | 2 | -1 | -0 | 1 | -0 | ||||||
| Retained Earnings Accumulated Deficit | 135 | 80 | 24 | -27 | -107 | -145 | -181 | -226 | -253 | -269 | -270 | -279 | ||||||
| Stockholders Equity | 1,359 | 1,277 | 1,220 | 1,138 | 1,041 | 985 | 946 | 886 | 839 | 799 | 779 | 756 | ||||||
| Liabilities And Stockholders Equity | 1,501 | 1,397 | 1,334 | 1,240 | 1,138 | 1,074 | 1,056 | 982 | 918 | 853 | 818 | 790 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | ||||||
| Common Stock Shares Issued | 30 | 29 | 29 | 29 | 29 | 29 | 29 | 29 | 29 | 29 | 28 | 28 | ||||||
| Shares Outstanding | 30 | 29 | 29 | 29 | 29 | 29 | 29 | 29 | 29 | 29 | 28 | 28 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialKrystal Biotech, Inc. (KRYS) — SEC Financial Statements & Analysis
Krystal Biotech, Inc. (KRYS) is a biological products, (no diagnostic substances) company. Krystal Biotech, Inc. trades on Nasdaq as: KRYS. Krystal Biotech, Inc. (KRYS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03. Based on that filing, Krystal Biotech, Inc. carries a market cap of $10.98B, a P/E ratio of 45.45x, a P/B ratio of 8.08x, a P/S ratio of 24.92x, an enterprise value of $10.55B, and an EV/EBITDA multiple of 51.78x. On profitability, it posts an operating margin of 44.89%, a net margin of 54.82%, a Return on Equity (ROE) of 20.12%, a Return on Assets (ROA) of 18.30%, and a Return on Invested Capital (ROIC) of 24.20%. Per share, it reports EPS of $8.18, diluted EPS of $7.88, free cash flow per share of $8.73, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 22.63% year-over-year, net income growth of 64.57% year-over-year, and EPS growth of 61.12% year-over-year. On the balance sheet, it maintains a current ratio of 8.32x, a quick ratio of 7.85x, working capital of $932.25M, a debt-to-equity ratio of 0.10x, a debt ratio of 0.09, an interest coverage ratio of 6.85x, free cash flow of $257.78M (TTM), and net debt of $-427.74M. Figures sourced from SEC EDGAR.
- Market Cap
- $10.98B
- P/E TTM
- 45.45x
- EPS TTM
- $8.18
- P/B TTM
- 8.08x
- ROE TTM
- 20.12%
- ROA TTM
- 18.30%
- Debt To Equity
- 0.10x
- Free Cash Flow TTM
- $257.78M
- Net Revenue TTM Growth 1Y
- 22.63%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Krystal Biotech, Inc. in?
Krystal Biotech, Inc. (KRYS) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does KRYS trade on?
Krystal Biotech, Inc. (KRYS) trades on the Nasdaq.
When was Krystal Biotech, Inc. (KRYS)'s most recent SEC filing?
Krystal Biotech, Inc. (KRYS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-03.
What is KRYS's market cap?
Krystal Biotech, Inc. (KRYS) has a market capitalization of $10.98B as of 2026-06-30.
What is KRYS's P/E ratio?
Krystal Biotech, Inc. (KRYS)'s trailing twelve month P/E ratio is 45.45x as of 2026-06-30.
What is KRYS's EPS (earnings per share)?
Krystal Biotech, Inc. (KRYS)'s trailing twelve month EPS is $8.18 as of 2026-06-30.
What is KRYS's ROE (return on equity)?
Krystal Biotech, Inc. (KRYS)'s trailing twelve month Return on Equity (ROE) is 20.12% as of 2026-06-30.
What is KRYS's ROA (return on assets)?
Krystal Biotech, Inc. (KRYS)'s trailing twelve month Return on Assets (ROA) is 18.30% as of 2026-06-30.
What is KRYS's ROIC (return on invested capital)?
Krystal Biotech, Inc. (KRYS)'s trailing twelve month Return on Invested Capital (ROIC) is 24.20% as of 2026-06-30.
What is KRYS's EV/EBITDA?
Krystal Biotech, Inc. (KRYS)'s trailing twelve month EV/EBITDA is 51.78x as of 2026-06-30.